Clovis warns of insolvency as Rubraca goes into reverse

Clovis Oncology has said it may not have enough cash to fund continuing operations beyond January next year, as it struggles to reverse a decline in sales of PARP inhibitor Rubraca.

PARP rivals close in on AZ and Merck's market leading Lynpar...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market s

New price gets Clovis’ PARP inhibitor on the CDF

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian c...

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest they could be used in a wide range of cancers as long as certa

Janssen CAR-T is Priority Medicine in EU, and more

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.